Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
Blood · 16.03.2023 · 141 (11) · 1265-1276
DOI: 10.1182/blood.2022016362 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Blood, erschienen am 16.03.2023. Verfasst von Naval G Daver und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Agents. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This phase 1b trial (NCT02670044) evaluated venetoclax-idasanutlin in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic chemotherapy. Two-dimensional dose escalation (DE, n = 50) was performed for venetoclax daily with idasanutlin on days 1 to 5 in 28-day cycles, followed by dosing schedule optimization (n = 6) to evaluate reduced venetoclax schedules (21-/14-day dosing). Common adverse events (occurring in ≥40% of patients) included diarrhea (87.3% of patients), nausea (74.5%), vomiting (52.7%), hypokalemia (50.9%), and febrile neutropenia (45.5%). During DE, across all doses, composite complete remission (CRc; CR + CR with incomplete blood count recovery + CR with incomplete platelet count recovery) rate was 26.0% and morphologic leukemia-free state (MLFS) rate was 12%. For anticipated recommended phase 2 doses (venetoclax 600 mg + idasanutlin 150 mg; venetoclax 600 mg + idasanutlin 200 mg), the combined CRc rate was 34.3% and the MLFS rate was 14.3%. Pretreatment IDH1/2 and RUNX1 mutations were associated with higher CRc rates (50.0% and 45.0%, respectively). CRc rate in patients with TP53 mutations was 20.0%, with responses noted among those with co-occurring IDH and RUNX1 mutations. In 12 out of 36 evaluable patients, 25 emergent TP53 mutations were observed; 22 were present at baseline with low TP53 variant allele frequency (median 0.0095% [range, 0.0006-0.4]). Venetoclax-idasanutlin showed manageable safety and encouraging efficacy in unfit patients with R/R AML. IDH1/2 and RUNX1 mutations were associated with venetoclax-idasanutlin sensitivity, even in some patients with co-occurring TP53 mutations; most emergent TP53 clones were preexisting. Our findings will aid ongoing/future trials of BCL-2/MDM2 inhibitor combinations. This trial was registered at www.clinicaltrials.gov as #NCT02670044.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Genentech, Inc, South San Francisco, CA.
- Dana-Farber Cancer Institute, Boston, MA.
- University of California Davis Comprehensive Cancer Center, Sacramento, CA.
- Princess Margaret Cancer Centre, Toronto, ON, Canada.
- Division of Hematology, University of Southern California, Los Angeles, CA.
ORCID-Profile: Naval G Daver, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Norbert Vey, Gail J Roboz, Stefania Paolini, Daniel A Pollyea, Joseph M Brandwein, Weize Huang, Cherie Green, Wan-Jen Hong, Marina Y Konopleva, Michael Andreeff
Zitieren
APA
Daver, N. G., Dail, M., Garcia, J. S., Jonas, B. A., Yee, K. W. L., Kelly, K. R., Vey, N., Assouline, S., Roboz, G. J., Paolini, S., Pollyea, D. A., Tafuri, A., Brandwein, J. M., Pigneux, A., Powell, B. L., Fenaux, P., Olin, R. L., Visani, G., Martinelli, G., …, & Andreeff, M. (2023). Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood, 141(11), 1265-1276. https://doi.org/10.1182/blood.2022016362
Vancouver
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, et al. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023;141(11):1265-1276. doi:10.1182/blood.2022016362
BibTeX
@article{Daver2023,
author = {Daver, Naval G and Dail, Monique and Garcia, Jacqueline S and Jonas, Brian A and Yee, Karen W L and Kelly, Kevin R and Vey, Norbert and Assouline, Sarit and Roboz, Gail J and Paolini, Stefania and Pollyea, Daniel A and Tafuri, Agostino and Brandwein, Joseph M and Pigneux, Arnaud and Powell, Bayard L and Fenaux, Pierre and Olin, Rebecca L and Visani, Giuseppe and Martinelli, Giovanni and Onishi, Maika and Wang, Jue and Huang, Weize and Green, Cherie and Ott, Marion G and Hong, Wan-Jen and Konopleva, Marina Y and Andreeff, Michael},
title = {Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial},
journal = {Blood},
year = {2023},
volume = {141},
number = {11},
pages = {1265--1276},
doi = {10.1182/blood.2022016362}
}
EUVIMED